SK279285B6 - Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin - Google Patents

Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin Download PDF

Info

Publication number
SK279285B6
SK279285B6 SK1306-92A SK130692A SK279285B6 SK 279285 B6 SK279285 B6 SK 279285B6 SK 130692 A SK130692 A SK 130692A SK 279285 B6 SK279285 B6 SK 279285B6
Authority
SK
Slovakia
Prior art keywords
dementia
improvement
iii
symptoms
compound
Prior art date
Application number
SK1306-92A
Other languages
English (en)
Slovak (sk)
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Tadashi Shiotani
Kazuo Hasegawa
Akira Honma
Original Assignee
Daiichi Pharmaceutical Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co. filed Critical Daiichi Pharmaceutical Co.
Publication of SK279285B6 publication Critical patent/SK279285B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1306-92A 1991-05-02 1992-04-29 Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin SK279285B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22981891 1991-05-02
JP22981991 1991-05-02

Publications (1)

Publication Number Publication Date
SK279285B6 true SK279285B6 (sk) 1998-09-09

Family

ID=26529012

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1306-92A SK279285B6 (sk) 1991-05-02 1992-04-29 Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin

Country Status (21)

Country Link
US (1) US5886023A (cs)
EP (1) EP0515866B1 (cs)
KR (1) KR100310590B1 (cs)
AT (1) ATE203402T1 (cs)
AU (2) AU1595492A (cs)
CA (1) CA2067614C (cs)
CZ (1) CZ281170B6 (cs)
DE (1) DE69231955T2 (cs)
DK (1) DK0515866T3 (cs)
ES (1) ES2160097T3 (cs)
GR (1) GR3036970T3 (cs)
HU (1) HU224689B1 (cs)
IE (1) IE921377A1 (cs)
IL (1) IL101738A (cs)
MX (1) MX9202058A (cs)
NO (1) NO312813B1 (cs)
PT (1) PT515866E (cs)
RU (1) RU2070042C1 (cs)
SG (1) SG49650A1 (cs)
SK (1) SK279285B6 (cs)
TW (1) TW199096B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727482B2 (en) 1996-10-01 2000-12-14 Daiichi Pharmaceutical Co., Ltd. Mitochondrial membrane stabilizer
DE69823851D1 (de) 1997-07-15 2004-06-17 Daiichi Seiyaku Co Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
CA2374921A1 (en) * 1999-05-31 2000-12-07 Shigeo Watabe Neuronal death inhibitors
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
JPWO2002053153A1 (ja) * 2000-12-28 2004-04-30 第一製薬株式会社 神経因性疼痛治療及び予防薬
JP2005501108A (ja) * 2001-08-22 2005-01-13 第一製薬株式会社 神経変性治療におけるネフィラセタムの使用
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
RU2327480C1 (ru) * 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
JP5917148B2 (ja) * 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
CA2789014C (en) * 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
JP6899043B2 (ja) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド レベチラセタムの持続放出性医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4385053A (en) * 1981-03-11 1983-05-24 Barry Reisberg Treatment for human memory impairment associated with aging
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti

Also Published As

Publication number Publication date
NO921724L (no) 1992-11-03
DE69231955T2 (de) 2002-04-04
US5886023A (en) 1999-03-23
HU9201477D0 (en) 1992-07-28
CS130692A3 (en) 1992-11-18
EP0515866B1 (en) 2001-07-25
PT515866E (pt) 2001-11-30
CA2067614A1 (en) 1992-11-03
DE69231955D1 (de) 2001-08-30
AU3774595A (en) 1996-03-07
AU1595492A (en) 1992-11-05
DK0515866T3 (da) 2001-09-24
KR100310590B1 (ko) 2001-12-28
HU224689B1 (hu) 2005-12-28
HK1002153A1 (en) 1998-07-31
GR3036970T3 (en) 2002-01-31
AU697936B2 (en) 1998-10-22
ATE203402T1 (de) 2001-08-15
ES2160097T3 (es) 2001-11-01
MX9202058A (es) 1993-03-01
NO312813B1 (no) 2002-07-08
NO921724D0 (no) 1992-04-30
CA2067614C (en) 2002-07-30
HUT62790A (en) 1993-06-28
RU2070042C1 (ru) 1996-12-10
CZ281170B6 (cs) 1996-07-17
IL101738A (en) 1999-01-26
TW199096B (cs) 1993-02-01
IE921377A1 (en) 1992-11-04
SG49650A1 (en) 1998-06-15
EP0515866A1 (en) 1992-12-02
KR920021143A (ko) 1992-12-18
IL101738A0 (en) 1992-12-30

Similar Documents

Publication Publication Date Title
SK279285B6 (sk) Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
Kassan et al. Clinical manifestations and early diagnosis of Sjögren syndrome
Thanvi et al. Update on myasthenia gravis
Cole Therapeutic efficacy of antidepressant drugs: a review
Chard et al. Shoulder disorders in the elderly (a hospital study).
JP7568651B2 (ja) ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
CN103906520A (zh) 用于治疗行为和精神病症的鲨肌醇
IE83506B1 (en) Use of N-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamide for the treatment of dementia
D'souza et al. Fetal phenytoin exposure, hypoplastic nails, and jitteriness.
Jablonski Jablonski's dictionary of medical acronyms & abbreviations
Reynolds et al. Rapid eye movement sleep deprivation as a probe in elderly subjects
Greenblatt et al. Physiologic changes in old age: relation to altered drug disposition
Farmakis et al. Safety of gadoterate meglumine in children younger than 2 years of age
Whorwell et al. Respiratory function in rheumatoid arthritis
Ferri et al. Agrypnia excitata in a patient with progeroid short stature and pigmented Nevi (Mulvihill‐Smith syndrome)
Bon et al. Paradoxical nrems distribution in “pure” chronic fatigue patients: a comparison with sleep apnea-hypopnea patients and healthy control subjects
Akshaya et al. A survey study of gender-related anxiety and fear on dental care among the patients visiting Saveetha Dental College and Hospital.
US7479506B2 (en) Agent or method for treating severe aphasia in cerebrovascular accident chronic stage
JP4120713B2 (ja) 多発性硬化症治療剤
Murthy et al. A double-blind evaluation of alprazolam and imipramine in the treatment of major depression
EP4547256A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
BANEN et al. Lorazepam versus Glutethimide as a Sleep‐Inducing Agent for the Geriatric Patient
Kraaijvanger et al. Neuroleptic malignant syndrome after overdose of haloperidol–A case report
EP4322946A1 (en) Treatment of prodromal huntington disease
WO2025189145A1 (en) Methods and compositions for treating wolfram syndrome